TMS 2025: Regina Castaneda, MD, on Tirzepatide, Menopause, and Hormone Therapy

At The Menopause Society’s 2025 Annual Meeting, Regina Castaneda, MD, a postdoctoral research fellow at the Mayo Clinic College of Medicine and Science in Jacksonville, FL, presented new data on how menopausal stage and hormone therapy use may influence weight loss outcomes with tirzepatide. In this interview with Patient Care, Dr Castaneda explains what prompted the study, how the findings compare with prior research on semaglutide, and why understanding the interplay between estrogen, reproductive stage, and GLP-1–based therapies could help clinicians personalize obesity treatment for midlife women.